Elfiky Aymen A, Sonpavde Guru
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.
Discov Med. 2012 Jun;13(73):461-71.
Emerging from a largely cytokine-based era, the last several years have witnessed a dramatic change in the therapeutic landscape of renal cancer. Molecularly targeted and antiangiogenic agents now form the backbone of most therapeutic strategies for patients with metastatic renal cell carcinoma (mRCC). Although the next few years may not see such broad paradigm shifts, there are ongoing areas of development including vaccine and immunotherapies which do diverge from this paradigm and hold promise to improve therapeutic outcomes for patients with mRCC.
在很大程度上基于细胞因子的时代之后，过去几年见证了肾癌治疗格局的巨大变化。分子靶向药物和抗血管生成药物现在构成了大多数转移性肾细胞癌（mRCC）患者治疗策略的核心。尽管未来几年可能不会出现如此广泛的模式转变，但仍有一些正在发展的领域，包括疫苗和免疫疗法，它们确实偏离了这一模式，并有望改善mRCC患者的治疗效果。
